Temozolomide (brand name Temodar®) is an oral alkylating agent used for the treatment of refractory anaplastic astrocytoma -- a type of cancerous brain tumour. A derivative of imidazotetrazine, temozolomide is the prodrug of MTIC (3-methyl-(triazen-1-yl)imidazole-4-carboxamide). Temodar is marketed by Schering Corporation, which also markets other well-known prescription drugs such as Clarinex, Nasonex, Levitra, Cipro, Vytorin, Diprolene, Elocon and Lotrisone.

Indications

Glioblastoma multiforme: for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as manitenance treatment.
Anaplastic astrocytoma: for the treatment of adult patients with refractory anaplastic atrocytoma (ie. patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine).
Unlabeled uses: Metastatic melanoma.

Dosage Forms

Temozolomide is available in the United States in 5mg, 20mg, 100mg, & 250mg capsules.

Read more at Wikipedia.org

• [List your site here Free!]

Research and Markets: Temozolomide Turns Heads in the Field of Brain Cancer
From Business Wire, 7/15/05

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c20845) has announced the addition of Stakeholder Opinions: Primary Brain Cancer - Temozolomide Turns Heads to their offering.

The incidence of glioblastoma is increasing. Schering-Plough's temozolomide has gained approval as first line therapy for glioblastoma and has provided some survival benefit. However, median survival is still a modest fifteen months. Thus, the glioblastoma market is characterized by a high level of unmet need and consequently lucrative commercial value.

This report provides an overview of disease including epidemiology, biology of glioma and prognostic variables. Current treatment options are analyzed and clinical controversies including comments from opinion leaders are included. The report provides key recommendations in the areas of greatest unmet need in glioblastoma patients together with profiles of agents in late stage development including opinions from glioma specialists.

Temozolomides approval as first line therapy for glioblastoma is a significant advance for these patients. The surge in US sales since its March 2005 approval reflects the current dearth in effective therapy for these patients. Temozolomide has raised the bar for other agents and, as such, physician expectation is now higher

Peregrines Cotara is in late stage development for glioblastoma. However, Datamonitor believes that Cotaras cumbersome administration and low physician awareness may hinder uptake

Opinion leaders feel the future for glioblastoma treatment will focus on novel targeted treatments. Eli Lilly's enzastaurin has demonstrated a 20% response rate in heavily pre-treated patients in Phase II trials, and may be the most promising early developmental agent at present. Phase III trials are planned combining enzastaurin with temozolomide

Reasons to Purchase

- Understand the limitations of current therapy available to glioma patients and the potential of future therapy

- Identify future market opportunities based on opinion leader comments regarding unmet needs, marketed products and those in the pipeline

- Plan new product development based on an understanding of physician expectation for improvements in survival, quality of life and economic constraints

For more information visit http://www.researchandmarkets.com/reports/c20845

Return to Temozolomide

Home

Contact

Resources

Exchange Links

ebay